Search results for "peak Vo2"

showing 2 items of 2 documents

Six-minute walk test in moderate to severe heart failure with preserved ejection fraction: Useful for functional capacity assessment?

2015

Despite improvements in medical treatment and prevention, heart failure (HF) remains a major cause of morbidity and mortality worldwide [1]. Currently, HF with preserved ejection fraction (HFpEF) has become the most prevalent form of HF in elderly patients [2,3]. The cardinal features in HF, aside from left ventricular systolic function, are exertional dyspnea and reduced aerobic capacity. Although the most accurate expression of exercise tolerance and severity in HF is measured by peak oxygen uptake (peak VO2), its assessment is not widely available in daily clinical practice.  This work was supported in part by grants from: Sociedad Española de Cardiología: Investigación Clínica en Cardio…

MaleModerate to severeGerontologySIX MINUTE WALKmedicine.medical_specialtyCapacity assessmentSix-minute walk testWalking030204 cardiovascular system & hematologySeverity of Illness Index03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumans030212 general & internal medicinePeak VO2AgedHeart Failurebusiness.industryDisease progressionStroke VolumeStroke volumemedicine.diseaseHeart failure with preserved ejection fractionHeart failureDisease ProgressionExercise TestCardiologyFunctional capacity assessmentFemaleCardiology and Cardiovascular MedicinePeak vo2Heart failure with preserved ejection fractionbusinessInternational Journal of Cardiology
researchProduct

Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction

2021

BACKGROUND Chronotropic incompetence has shown to be associated with a decrease in exercise capacity in heart failure with preserved ejection fraction (HFpEF), yet b-blockers are commonly used in HFpEF despite the lack of robust evidence. OBJECTIVES This study aimed to evaluate the effect of b-blocker withdrawal on peak oxygen consumption (peak VO2) in patients with HFpEF and chronotropic incompetence. METHODS This is a multicenter, randomized, investigator-blinded, crossover clinical trial consisting of 2 treatment periods of 2 weeks separated by a washout period of 2 weeks. Patients with stable HFpEF, New York Heart Association functional classes II and III, previous treatment with b-bloc…

medicine.medical_specialtyanimal structuresEjection fractionpeak Vo2chronotropic incompetencebusiness.industryChronotropic incompetencepercentage of predicted peakVo2Exercise capacitymedicine.diseaseHFpEFCrossover studyHeart failureInternal medicineHeart ratemedicineCardiologyβ-blockersheart ratecrossover trialCardiology and Cardiovascular MedicinePeak vo2Heart failure with preserved ejection fractionbusiness
researchProduct